MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Rivastigmine"

  • 2025 International Congress

    The Effectiveness of Rivastigmine in Parkinson’s Disease: Impact on Motor Symptoms, Gait, Cognitive Function, and Falls – A Systematic Review and Meta-Analysis of Double-Blind, Placebo-Controlled RCTs

    V. Byroju, J. Pitton Rissardo, A. Fornari Caprara (Camden, USA)

    Objective: To evaluate the efficacy of rivastigmine in patients with Parkinson’s disease (PD) by assessing its impact on motor symptoms, cognitive function, gait, falls, and…
  • MDS Virtual Congress 2020

    CHIEF-PD: Cholinesterase Inhibitor to prEvent Falls in Parkinson’s Disease

    S. Neumann, J. Taylor, A. Bamford, C. Metcalfe, D.M Gaunt, A. Whone, D. Steeds, S.R Emmett, W. Hollingworth, Y. Ben-Shlomo, E. Henderson (Bristol, United Kingdom)

    Objective: Preventing falls in people with Parkinson’s disease has the potential to reduce hospital admissions and improve quality of life by diminishing the significant morbidity…
  • 2019 International Congress

    Rivastigmine for visual hallucinations in Parkinson’s disease

    T. Mierlo, E. Foncke, R. Bie (Amsterdam, Netherlands)

    Objective: The aim of the study is to investigate whether early rivastigmine treatment of visual hallucinations in patients with Parkinson's disease delays the progression of…
  • 2018 International Congress

    An open labeled, observational study for the Satisfaction and Preference of the Rivastigmine patch for treatment of Alzheimer’s disease and Parkinson’s disease dementia (SAFE-ADPD) in Koreans

    M. Park, D. Shin (Daegu, Republic of Korea)

    Objective: This study performed to access caregiver’s satisfaction and preference of the Rivastigmine patch for treatment of Alzheimer’s disease and Parkinson’s disease dementia patients to…
  • 2018 International Congress

    Rivastigmine solution in the one-year treatment of Parkinson’s disease dementia and dementia with Lewy bodies

    P.Y. Chiu (Changhua, Taiwan)

    Objective: Efficacy and safety of rivastigmine solution in the treatment of dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) is not well studied…
  • 2017 International Congress

    Do Acetylcholinesterase Inhibitors (AChEI) delay institutionalisation in Parkinson’s and Lewy Body Disease?

    L. Brown, B. Mohamed, E. Thomas (Cardiff, United Kingdom)

    Objective: We explored the use of Rivastigmine in Parkinson’s and Lewy body dementia through assessment of quantitative data obtained from a clinical database. We focussed…
  • 2016 International Congress

    Effect of rivastigmine in Parkinson’s disease dementia – A logitudinal observational study

    S. Raha, L. Ebenezer (Bridgend, United Kingdom)

    Objective: Outcome of Rivastigmine treatment in Parkinson's disease Dementia (PDD). Effect of treatment on cognition and Neuropsychiatric symptoms. To compare clinical global impression of Clinicians…

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley